FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965894932> ?p ?o ?g. }

• W1965894932 endingPage "289" @default.
• W1965894932 startingPage "279" @default.
• W1965894932 abstract "Most patients with hypertension in the United States and Europe fail to achieve the recommended target blood pressure (BP) of <140/90 mm Hg. Combination therapy is required in approximately two thirds of all patients whose BP is >20/10 mm Hg above the goal. Combination therapy with agents having complementary mechanisms of action, such as a calcium channel blocker and an angiotensin II-receptor blacker, would be a potentially useful therapeutic option.This study evaluated the overall safety profile of combination therapy with amlodipine plus valsartan compared with a combination of lisinopril plus hydrochlorothiazide (HCTZ) in patients with stage 2 hypertension (mean sitting diastolic BP [MSDBP] >or=110 and <120 mm Hg) over the short term (6 weeks). A secondary objective was to evaluate the efficacy of the 2 regimens in achieving BP reduction.This was an international, multicenter, randomized, double-blind, active-controlled, parallel-group study. Patients were randomized to receive once-daily treatment with amlodipine 5 to 10 mg + valsartan 160 mg or lisinopril 10 to 20 mg + HCTZ 12.5 rig for 6 weeks. Safety assessments included monitoring of all adverse events, vital signs, and hematology and biochemistry variables. Efficacy variables included the changes from baseline in MSDBP and mean sitting systolic BP (MSSBP), the response rate (MSDBP <90 mm Hg, or a >or= 10-mm Hg reduction from baseline), and the rate of DBP control (<90 mm Hg). The overall rate of BP control (proportion of patients with MSSBP/MSDBP <140/90 mm Hg) was evaluated in a post hoc analysis. Efficacy variables were summarized at each visit and at the end of the study (week 6, applying last-observation-carried-forward methodology) using descriptive statistics for the intent-to-treat population (all randomized patients with a baseline BP measurement and at least 1 post baseline BP measurement). Subgroup analyses of BP changes were performed in prespecified age groups (<65 and >or=65 years) and post hoc in patients with a baseline systolic BP <180 and >or=180 mm Hg.: Of 130 patients who were randomized to treatment, 128 completed the study: 63 in the amlodipine + valsartan group and 65 in the lisinopril + HCTZ group. The majority of patients in both groups were white (amlodipine + valsartan: 59.4% lisinopril + HCTZ: 60.6%) and female (57.8% and 54.5%, respectively). The mean age was similar in the 2 groups (56.5 and 57.6 years), as was the mean weight (85.1 and 82.0 kg). Both regimens were generally well tolerated. Adverse events were mild to moderate in severity, and most were not considered related to study drug. At the 6-week end point, both the amlodipine + valsartan and lisinopril + HCTZ groups had achieved significant reductions from baseline in MSSBP (-35.8 [11.8] and -31.8 [14.7] mm Hg, respectively; both, P < 0.001) and MSDBP (-28.6 [7.7] and -27.6 [8.6] mm Hg; both, P < 0.001). Response rates were similar for the 2 treatment groups (100% and 95.5%), as were rates of DBP control (79.7% and 77.3%).: The combinations of amlodipine 5 to 10 rug + valsartan 160 mg and lisinopril 10 to 20 mg + HCTZ 12.5 mg were well tolerated and efficacious, and both treatments were associated with achievement of BP goals in the majority of these adult patients with stage 2 hypertension." @default.
• W1965894932 created "2016-06-24" @default.
• W1965894932 creator A5005453947 @default.
• W1965894932 creator A5018693300 @default.
• W1965894932 creator A5020928038 @default.
• W1965894932 creator A5032525415 @default.
• W1965894932 creator A5052701170 @default.
• W1965894932 creator A5055303650 @default.
• W1965894932 creator A5062484938 @default.
• W1965894932 creator A5080641025 @default.
• W1965894932 creator A5081151097 @default.
• W1965894932 date "2007-02-01" @default.
• W1965894932 modified "2023-10-18" @default.
• W1965894932 title "Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension" @default.
• W1965894932 cites W119726640 @default.
• W1965894932 cites W1964849117 @default.
• W1965894932 cites W1993410366 @default.
• W1965894932 cites W2007864101 @default.
• W1965894932 cites W2025631096 @default.
• W1965894932 cites W2044255545 @default.
• W1965894932 cites W2044773944 @default.
• W1965894932 cites W2049397775 @default.
• W1965894932 cites W2066505246 @default.
• W1965894932 cites W2068908293 @default.
• W1965894932 cites W2106057198 @default.
• W1965894932 cites W2120309176 @default.
• W1965894932 cites W2130433171 @default.
• W1965894932 cites W2131494018 @default.
• W1965894932 cites W2132660976 @default.
• W1965894932 cites W2137704829 @default.
• W1965894932 cites W2143954917 @default.
• W1965894932 cites W2151865548 @default.
• W1965894932 cites W2155441883 @default.
• W1965894932 cites W3034187217 @default.
• W1965894932 cites W3145527833 @default.
• W1965894932 cites W3198570063 @default.
• W1965894932 cites W4246169631 @default.
• W1965894932 cites W75245760 @default.
• W1965894932 cites W7687383 @default.
• W1965894932 doi "https://doi.org/10.1016/j.clinthera.2007.02.003" @default.
• W1965894932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17472820" @default.
• W1965894932 hasPublicationYear "2007" @default.
• W1965894932 type Work @default.
• W1965894932 sameAs 1965894932 @default.
• W1965894932 citedByCount "97" @default.
• W1965894932 countsByYear W19658949322012 @default.
• W1965894932 countsByYear W19658949322013 @default.
• W1965894932 countsByYear W19658949322014 @default.
• W1965894932 countsByYear W19658949322015 @default.
• W1965894932 countsByYear W19658949322018 @default.
• W1965894932 countsByYear W19658949322020 @default.
• W1965894932 countsByYear W19658949322022 @default.
• W1965894932 countsByYear W19658949322023 @default.
• W1965894932 crossrefType "journal-article" @default.
• W1965894932 hasAuthorship W1965894932A5005453947 @default.
• W1965894932 hasAuthorship W1965894932A5018693300 @default.
• W1965894932 hasAuthorship W1965894932A5020928038 @default.
• W1965894932 hasAuthorship W1965894932A5032525415 @default.
• W1965894932 hasAuthorship W1965894932A5052701170 @default.
• W1965894932 hasAuthorship W1965894932A5055303650 @default.
• W1965894932 hasAuthorship W1965894932A5062484938 @default.
• W1965894932 hasAuthorship W1965894932A5080641025 @default.
• W1965894932 hasAuthorship W1965894932A5081151097 @default.
• W1965894932 hasConcept C126322002 @default.
• W1965894932 hasConcept C126894567 @default.
• W1965894932 hasConcept C164705383 @default.
• W1965894932 hasConcept C197934379 @default.
• W1965894932 hasConcept C27016395 @default.
• W1965894932 hasConcept C2776999253 @default.
• W1965894932 hasConcept C2777387769 @default.
• W1965894932 hasConcept C2777880890 @default.
• W1965894932 hasConcept C2778375690 @default.
• W1965894932 hasConcept C2779646130 @default.
• W1965894932 hasConcept C2780361556 @default.
• W1965894932 hasConcept C71924100 @default.
• W1965894932 hasConcept C84393581 @default.
• W1965894932 hasConceptScore W1965894932C126322002 @default.
• W1965894932 hasConceptScore W1965894932C126894567 @default.
• W1965894932 hasConceptScore W1965894932C164705383 @default.
• W1965894932 hasConceptScore W1965894932C197934379 @default.
• W1965894932 hasConceptScore W1965894932C27016395 @default.
• W1965894932 hasConceptScore W1965894932C2776999253 @default.
• W1965894932 hasConceptScore W1965894932C2777387769 @default.
• W1965894932 hasConceptScore W1965894932C2777880890 @default.
• W1965894932 hasConceptScore W1965894932C2778375690 @default.
• W1965894932 hasConceptScore W1965894932C2779646130 @default.
• W1965894932 hasConceptScore W1965894932C2780361556 @default.
• W1965894932 hasConceptScore W1965894932C71924100 @default.
• W1965894932 hasConceptScore W1965894932C84393581 @default.
• W1965894932 hasIssue "2" @default.
• W1965894932 hasLocation W19658949321 @default.
• W1965894932 hasLocation W19658949322 @default.
• W1965894932 hasOpenAccess W1965894932 @default.
• W1965894932 hasPrimaryLocation W19658949321 @default.
• W1965894932 hasRelatedWork W1965894932 @default.
• W1965894932 hasRelatedWork W1986866289 @default.
• W1965894932 hasRelatedWork W2013747044 @default.
• W1965894932 hasRelatedWork W2049351459 @default.

• next